Develops antibody-based drug candidates that target the Wnt tissue-repair pathway for serious eye diseases, including retinal conditions.
10-K for FY2025, filed Mar 23, 2026We are a biotechnology company committed to discovering and developing product candidates to selectively modulate the Wnt pathway, a…View ↗
Our lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt proteins, which…View ↗
We are developing SZN-8141 for the treatment of diabetic macular edema, or DME, and neovascular age-related macular degeneration, or wet…View ↗
We are developing SZN-8143 for the treatment of DME, wet AMD, and uveitic macular edema, or UME. SZN-8143 combines Fzd4 agonism, VEGF…View ↗
It receives fees for antibody-discovery services over time; licensing arrangements can also bring upfront and milestone payments and royalties on licensed-product sales.
10-K for FY2025, filed Mar 23, 2026In October 2022, we executed a Collaboration and Licensing Agreement, or the CLA, with Boehringer Ingelheim International GmbH, or…View ↗
In October 2024, we entered into a strategic research collaboration with a privately-held company, TCGFB, Inc., or TCGFB, to discover…View ↗
We had not generated any revenue prior to the execution of the CLA in October 2022. Under the terms of the CLA, Boehringer Ingelheim paid…View ↗
Services: Service fees are recognized over time based on progress toward complete satisfaction of the performance obligation. For each…View ↗
Milestone Payments: At contract inception, the Company uses the most likely amount method evaluates whether the milestones are considered…View ↗
Royalties: The Company recognizes sales-based royalties as revenue at the later of (i) when the related sales occur, or (ii) when the…View ↗
10-K for FY2025, filed Mar 23, 2026
FY2025 revenue by product or service ↗$3.5M
10-K for FY2025, filed Mar 23, 2026
$3.5M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Research service revenue
Recurring
10-K for FY2025, filed Mar 23, 2026 |
100% |
Research service revenue, FY2025
$3.5M Sources
|
Recurring |
|
Collaboration and license revenue
Licensed
|
0.0% |
Collaboration and license revenue, FY2025
$0 Sources
|
Licensed |
Works directly with TCGFB on antibody-discovery services and licenses Fzd4 antibody candidates to Boehringer Ingelheim, which handles further development, manufacturing and commercialization.
10-K for FY2025, filed Mar 23, 2026
No. It lost $242M in FY2025.
Focus on eye disease
The company described programs across multiple organs, including intestine and liver, and Wnt and R-spondin approaches. It now focuses on ophthalmology, with candidates and research programs aimed at eye diseases.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 23, 2026We are a biotechnology company committed to discovering and developing product candidates to selectively modulate the Wnt pathway, a…View ↗
Our lead product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt proteins, which…View ↗
In addition to SZN-8141 and SZN-8143, we are evaluating research-stage programs focused on other ophthalmic indications where Wnt signaling…View ↗
Competes with Roche, Regeneron, Novartis, Bayer, AbbVie, Boehringer Ingelheim, Amgen, Merck, Sanofi, Eli Lilly, and Samsung Bioepis
10-K for FY2025, filed Mar 23, 2026There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development of products for the…View ↗
Loading...